TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Year, New Registries Added to TrialScope Disclose

newseditor

January 20, 2021

Industry’s Leading Clinical Trial Disclosure Management Platform
Supports 8 More Global Registries

JERSEY CITY, NJ, Jan. 20, 2021 – TrialScope, the global leader in clinical trial disclosure and transparency technology, has expanded its TrialScope Disclose platform to a total of 37 global registries. In addition to the ClinicalTrials.gov and EudraCT registries for the U.S. and EU, respectively, the latest software release for TrialScope Disclose includes automated rules to determine if and when disclosure is required for the following registries, covering everything from protocol registration to clinical trial agreements and results reporting:

  • AGES (Austria)
  • IRPMA PMS (Taiwan)
  • ISRCTN (UK)
  • JAPIC & JRCT (Japan)
  • PPB (Kenya)
  • REPEC (Peru)
  • SNCTP (Switzerland)

Nearly half (47 percent) of all clinical trials are conducted globally. This means that study sponsors are responsible for registering studies, as well as updating them, with multiple regulatory agencies in countries where the trials are based. Because there are no global disclosure standards, sponsors face the daunting task of complying with a myriad of regulatory requirements.

Francine Lane, TrialScope Vice President of Global Transparency, noted that global clinical trial disclosure regulations are constantly changing, necessitating regular updates to the TrialScope Disclose platform, which supports customers responsible for more than 40 percent of industry studies registered on ClinicalTrials.gov and EudraCT alone. “We stay on top of global disclosure laws so that our customers don’t have to. Our goal is to make disclosure management and compliance as easy as possible for our customers, which is why our automated rules engine has proven invaluable to them.” She added that the coronavirus pandemic has placed clinical trial sponsors under a microscope, with the public demanding greater transparency and accountability.

The update includes the ability for sponsors to report compliance against various dates for each registry, such as the legal compliance date, company policy dates and manual override dates. Many sponsors have internal policies that require disclosure on a stricter timeline than the regulatory or legal requirements. TrialScope customers can stratify their level of compliance against these various internal and external obligations.

To learn more about TrialScope Disclose, visit TrialScope.com or contact TrialScope at hello@trialscope.com or +1 877-658-8310.

About TrialScope 

TrialScope gives your clinical trial data superpowers™. The TrialScope Transparency Cloud™ makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit TrialScope.com.

TrialScope was acquired by Informa Pharma Intelligence in 2020, combining its powerful technology for disclosure, transparency and recruitment with leading brands, data and solutions for the clinical trials and broader pharmaceutical and biomedical industry.

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Medtrack™, Biomedtracker™, Scrip™, Pink Sheet™ In Vivo™ and most recently TrialScope– to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.